Roquefort Therapeutics PLC - London-based biotechnology company focused on oncology market - Announces the successful development of a new novel platform of anti-cancer mRNA therapeutics. Says this is its fifth programme and the third in its Midkine family. The new platform consists of four mRNA pre-clinical therapeutics targeting Roquefort’s Midkine target. Midkine is a human growth factor associated with cancer progression. Says it is now working towards demonstrating efficacy of the mRNA therapeutics in specific cancer targets, alongside the its existing oligonucleotide Midkine programme.

Current stock price: 7.55 pence, down 4.1% in London on Wednesday afternoon

12-month change: down 17%

Copyright 2022 Alliance News Ltd. All Rights Reserved.